nach oben

Current Rheumatology Reports

Erschienen in:

01.06.2018 | Crystal Arthritis (L Stamp, Section Editor)

Therapy for CPPD: Options and Evidence

verfasst von: Mariano Andrés, Francisca Sivera, Eliseo Pascual

Erschienen in: Current Rheumatology Reports | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Current evidence and accumulated experience for the management of calcium pyrophosphate deposition disease (CPPD) are presented.

Recent Findings

Contrary to other rheumatic inflammatory conditions that account for high interest and growing research, advances in treating CPPD are still very limited and mostly derive from those achieved in gout.

Summary

Once formed, calcium pyrophosphate crystals cannot be dissolved; therefore, management relies on the control of crystal-derived inflammation. Besides classical agents—such as colchicine, glucocorticoids, or NSAIDs—the use of targeted therapies, mostly against interleukin-1, has provided a relevant relief for refractory CPPD patients in recent years. Meanwhile, former enthusiasm about conventional disease-modifying agents such as methotrexate is currently controversial.

Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. 2011;70:563–70.CrossRefPubMed

Richette P, Bardin T, Doherty M. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology (Oxford). 2009;48:711–5.CrossRef

Abreu M, Johnson K, Chung CB, de Lima JE, Trudell D, Terkeltaub R, et al. Calcification in calcium pyrophosphate dihydrate (CPPD) crystalline deposits in the knee: anatomic, radiographic, MR imaging, and histologic study in cadavers. Skelet Radiol. 2004 Jul;33(7):392–8.CrossRef

Sivera F, Andres M, Pascual E. Current advances in therapies for calcium pyrophosphate crystal arthritis. Curr Opin Rheumatol. 2016;28(2):140–4.CrossRefPubMed

Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;6:29–42.CrossRef

Zhang W, Doherty M, Pascual E, Barsrkova V, Guerne PA, Jansen TL, et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis. 2011;70(4):571–5.CrossRefPubMed

Solomon DH, Husni ME, Libby PA, Yeomans ND, Lincoff AM, Lüscher TF, et al. The risk of major NSAID toxicity with celecoxib, ibuprofen or naproxen: a secondary analysis of the PRECISION trial. Am J Med. 2017;130(12):1415–22.CrossRefPubMed

Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64:1447–61.CrossRef

Daoussis D, Antonopoulos I, Yiannopoulos G, Andonopoulos AP. ACTH as first line treatment for acute calcium pyrophosphate crystal arthritis in 14 hospitalized patients. Joint Bone Spine. 2014;81:98–100.CrossRefPubMed

10.

Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare. Twenty-four hour outcome of hte first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060–8.CrossRefPubMed

11.

Alvarellos A, Spilberg I. Colchicine prophylaxis in pseudogout. J Rheumatol. 1986;13(4):804–5.PubMed

12.

Gonzalez T, Gantes M. Prevention of acute attacks of pseudogout with oral colchicine. J Rheumatol. 1987;14(3):632–3.PubMed

13.

Das SK, Ramakrishnan S, Mishra K, Srivastava R, Agarwal GG, Singh R, et al. A randomized controlled trial to evaluate the slow-acting symptom-modifying effects of colchicine in osteoarthritis of the knee: a preliminary report. Arthritis Rheum. 2002;47(3):280–4.CrossRefPubMed

14.

Guerne PA, Terkeltaub R. Calcium pyrophospahte dihydrate crystal deposition: epidemiology, clinical features, diagnosis and treatment. In: Terkeltaub R, editor. Gout and other crystal arthropathies; 2012. Elsevier. Philadelphia: Saunders; 2012. p. 249–65.CrossRef

15.

Abhishek A, Doherty M. Update on calcium pyrophosphate deposition. Clin Exp Rheumatol. 2016;34(4 Suppl 98):32–8.PubMed

16.

Ryan LM, McCarty DJ. Calcium pyrophosphate crystal deposition disease; pseudogout; articular chondrocalcinosis. In: McCarty DJ, editor. Arthritis and allied conditions. 10th ed. Philadelphia: Lea & Febiger; 1985. p. 1515–46.

17.

Rothschild B, Yakubov LE. Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD. Compr Ther. 1997;23:327–31.PubMed

18.

Chollet-Janin A, Finckh A, Dudler J, Guerne PA. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum. 2007;56:688–92.CrossRefPubMed

19.

Doan TH, Chevalier X, Leparc JM, et al. Premature enthusiasm for the use of methotrexate for refractory chondrocalcinosis: comment on the article by Chollet-Janin et al. Arthritis Rheum. 2008;58:2210–1.CrossRefPubMed

20.

Andres M, Sivera F, Pascual E. Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis. J Clin Rheumatol. 2012;18:234–6.CrossRefPubMed

21.

Finckh A, Mc Carthy GM, Madigan A, van Linthoudt D, Weber M, Neto D, et al. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther. 2014;16:458.CrossRefPubMedPubMedCentral

22.

•• Pascual E, Andrés M, Sivera F. Methotrexate: should it still be considered for chronic calcium pyrophosphate crystal disease? Arthritis Res Ther. 2015;17:89. The possibility that a symmetrical seronegative rheumatoid arthritis-like polyarthritis in an elderly person responding to methotrexate treatment is a real seronegative RA in a patient coincidentally having CPP crystals in their joints is a possibility that has to be considered CrossRefPubMedPubMedCentral

23.

Bergström G, Bjelle A, Sundh V, et al. Joint disorders at ages 70, 75 and79 years—a cross-sectional comparison. Br J Rheumatol. 1986;25:333–41.CrossRefPubMed

24.

Felson DT, Anderson JJ, Naimark A, Kannel W, Meenan RF. The prevalence of chondrocalcinosis in the elderly and its association with knee osteoarthritis: the Framingham Study. J Rheumatol. 1989;16(9):1241–5.PubMed

25.

Sanmartí R, Pañella D, Brancós MA, et al. Prevalence of articular chondrocalcinosis in elderly subjects in a rural area of Catalonia. Ann Rheum Dis. 1993 Jun;52(6):418–22.CrossRefPubMedPubMedCentral

26.

Neame RL, Carr AJ, Muir K, Doherty M. UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. Ann Rheum Dis. 2003;62:513–8.CrossRefPubMedPubMedCentral

27.

Ramonda R, Musacchio E, Perissinotto E, et al. Prevalence of chondrocalcinosis in Italian subjects from northeastern Italy. The Pro.V.A. (PROgetto Veneto Anziani) study. Clin Exp Rheumatol. 2009;27:981–4.PubMed

28.

Theiler G, Quehenberger F, Rainer F, Neubauer M, Stettin M, Robier C. The detection of calcium pyrophosphate crystals in the synovial fluid of patients with rheumatoid arthritis using the cytospin technique: prevalence and clinical correlation. Rheumatol Int. 2014;34:137–9.CrossRefPubMed

29.

Oliviero F, Scanu A, Galozzi P, Gava A, Frallonardo P, Ramonda R, et al. Prevalence of calcium pyrophosphate and monosodium urate crystals in synovial fluid of patients with previously diagnosed joint diseases. Joint Bone Spine. 2013;80:287–90.CrossRefPubMed

30.

Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237–41.CrossRefPubMed

31.

Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016;374:2575–84.CrossRefPubMed

32.

McGonagle D, Tan AL, Madden J, Emery P, McDermott MF. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum. 2008;58:631–3.CrossRefPubMed

33.

Announ N, Palmer G, Guerne PA, Gabay C. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine. 2009;76:424–6.CrossRefPubMed

34.

Couderc M, Mathieu S, Glace B, Soubrier M. Efficacy of anakinra in articular chondrocalcinosis: report of three cases. Joint Bone Spine. 2012;79:330–1.CrossRefPubMed

35.

Moltó A, Ea HK, Richette P, Bardin T, Lioté F. Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis. Joint Bone Spine. 2012;79:621–3.CrossRefPubMed

36.

Diamantopoulos AP, Brodin C, Hetland H, Haugeberg G. Interleukin 1β blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment. J ClinRheumatol. 2012;18:310–1.

37.

Ottaviani S, Brunier L, Sibilia J, Maurier F, Ardizzone M, Wendling D, et al. Efficacy of anakinra in calcium pyrophosphatecrystal-induced arthritis: a report of 16 cases and review of the literature. Joint Bone Spine. 2013;80:178–82.CrossRefPubMed

38.

• Aouba A, Deshayes S, Frenzel L, et al. Efficacy of anakinra for various types of crystal-induced arthritis in complex hospitalized patients: a case series and review of the literature. Mediators Inflamm. 2015;2015:792173. When the usual treatments for acute flares of CPP arthritis are contraindicated—most often because of comorbidities—, a short course of anakinra offers an effective and safe alternative. CrossRefPubMedPubMedCentral

39.

Dumusc A, Pazar Maldonado B, et al. Anakinra compared to prednisone on the treatment of acute CPPD crystal arthritis, a randomized, controlled, double-blind study [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10).

40.

Quilis N, Andrés M, Vela P, Pascual E. Interleukin-6 pathway blockade as an option for managing refractory cases of crystal arthritis: two cases report. Joint Bone Spine. 2017; https://doi.org/10.1016/j.jbspin.2017.04.008.

41.

Guerne PA, Terkeltaub R, Zuraw B, Lotz M. Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum. 1989;32:1443–52.CrossRefPubMed

42.

Dietvorst M, Roerdink R, Leenders ACAP, Kiel MA, Bom LPA. Acute mono-arthritis of the knee: a case report of infection with parvimonas micra and concomitant pseudogout. J Bone Jt Infect. 2016;1:65–7.CrossRefPubMedPubMedCentral

43.

Fernández C, Noguera R, González JA, Pascual E. Treatment of acute gouty attacks with a small dose of intra-articular triamcinolone acetonide. J Rheumatol. 1999;26:2285–6.PubMed

44.

Doherty M, Dieppe PA. Effect of intra-articular yttrium-90 on chronic pyrophosphate arthropathy of the knee. Lancet. 1981;2(8258):1243–6.CrossRefPubMed

45.

Kumar V, Pandit HG, Liddle AD, Borror W, Jenkins C, Mellon SJ, et al. Comparison of outcomes after UKA in patients with and without chondrocalcinosis: a matched cohort study. Knee Surg SportsTraumatol Arthrosc. 2017;25:319–24.CrossRef

46.

Lee G-C, Lotke PA. Does chondrocalcinosis affect knee society scores and range of motion after TKA? Clin Orthop Relat Res. 2014;472:1512–7.CrossRefPubMedPubMedCentral

47.

• Yahia SA, Zeller V, Desplaces N, Chazerain P, Lhotellier L, Marmor S, et al. Crystal-induced arthritis after arthroplasty: 7 cases. Joint Bone Spine. 2016;83:559–62. Acute arthritis after arthroplasty can result from CPP—or MSU—crystals, likely present previous to the procedure. Besides culture, a synovial fluid analysis searching for crystals should be done. Crystals and organisms can occur together, and culture must be done even if crystals are found CrossRefPubMed

48.

Disla E, Infante R, Fahmy A, Karten I, Cuppari GG. Recurrent acute calcium pyrophosphate dihydrate arthritis following intraarticular hyaluronate injection. Arthritis Rheum. 1999;42:1302–3.CrossRefPubMed

Titel: Therapy for CPPD: Options and Evidence
verfasst von: Mariano Andrés
Francisca Sivera
Eliseo Pascual
Publikationsdatum: 01.06.2018
Verlag: Springer US
Erschienen in: Current Rheumatology Reports / Ausgabe 6/2018
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-018-0739-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

20.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Therapy for CPPD: Options and Evidence

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

New Trials in Lupus and where Are we Going

Therapeutic Approaches to Type I Interferonopathies

Current Options and Emerging Biomaterials for Periprosthetic Joint Infection

Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Update Innere Medizin